Junxuan Lü Selected Research

pentagalloylglucose

8/2011	Penta-1,2,3,4,6-O-galloyl-beta-D-glucose induces senescence-like terminal S-phase arrest in human hepatoma and breast cancer cells.
6/2011	Oral administration of penta-O-galloyl-β-D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition.
10/2010	Anti-cancer gallotannin penta-O-galloyl-beta-D-glucose is a nanomolar inhibitor of select mammalian DNA polymerases.
10/2009	Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells.
5/2009	Penta-O-galloyl-beta-D-glucose induces S- and G(1)-cell cycle arrests in prostate cancer cells targeting DNA replication and cyclin D1.
9/2008	Penta-1,2,3,4,6-O-galloyl-beta-D-glucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Junxuan Lü Research Topics

Disease

46	Neoplasms (Cancer) 01/2021 - 07/2002
38	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 07/2002
10	Carcinogenesis 01/2022 - 09/2006
9	Adenocarcinoma 01/2021 - 05/2009
7	Inflammation (Inflammations) 01/2020 - 09/2009
5	Body Weight (Weight, Body) 01/2022 - 03/2009
5	Neuroendocrine Carcinoma 01/2022 - 05/2009
5	Neoplasm Metastasis (Metastasis) 01/2017 - 12/2006
4	Breast Neoplasms (Breast Cancer) 12/2012 - 09/2006
4	Lung Neoplasms (Lung Cancer) 12/2012 - 06/2007
3	Leukemia 12/2012 - 07/2002
3	Hypoxia (Hypoxemia) 01/2010 - 12/2006
3	Carcinoma (Carcinomatosis) 03/2009 - 07/2002
2	Prostatic Intraepithelial Neoplasia 01/2020 - 01/2016
2	Rheumatic Diseases (Rheumatism) 12/2015 - 12/2012
2	Anemia 12/2015 - 12/2012
2	Pain (Aches) 12/2015 - 12/2012
2	Infections 12/2015 - 12/2012
2	Sarcoma (Soft Tissue Sarcoma) 12/2012 - 06/2007
2	Lewis Lung Carcinoma 06/2007 - 12/2006
1	Disease Progression 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2014
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2012
1	Colonic Neoplasms (Colon Cancer) 12/2012
1	Hyperplasia 09/2011
1	Hepatocellular Carcinoma (Hepatoma) 08/2011
1	Triple Negative Breast Neoplasms 06/2011
1	Endometriosis 01/2011

Drug/Important Bio-Agent (IBA)

18	SeleniumIBA 01/2022 - 10/2002
14	methylselenic acidIBA 01/2022 - 10/2002
10	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 05/2009
9	methaneselenolIBA 01/2016 - 07/2002
9	Prostaglandins GIBA 08/2011 - 09/2008
8	Selenium CompoundsIBA 08/2010 - 07/2002
7	AndrogensIBA 01/2022 - 05/2004
7	Messenger RNA (mRNA)IBA 01/2021 - 06/2007
7	decursinIBA 01/2021 - 01/2009
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2007
6	Selenomethionine (Sethotope)FDA Link 01/2022 - 05/2008
6	Ethanol (Ethyl Alcohol)IBA 01/2021 - 12/2006
6	pentagalloylglucoseIBA 08/2011 - 09/2008
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2011 - 12/2006
6	Selenious Acid (Selenite)IBA 01/2011 - 10/2002
5	selenomethylselenocysteine (methylselenocysteine)IBA 01/2022 - 03/2009
5	TensinsIBA 01/2022 - 08/2005
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 05/2004
5	PENTAIBA 06/2011 - 05/2009
5	CaspasesIBA 10/2009 - 07/2002
4	Phosphotransferases (Kinase)IBA 01/2016 - 03/2009
4	Tannic Acid FDA Link 08/2011 - 05/2009
4	DNA (Deoxyribonucleic Acid)IBA 10/2010 - 07/2004
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022 - 01/2016
3	PyranocoumarinsIBA 01/2021 - 09/2015
3	beta-d-glucoseIBA 02/2011 - 05/2009
3	Pharmaceutical PreparationsIBA 02/2010 - 02/2008
2	CarcinogensIBA 01/2022 - 09/2006
2	Hormones (Hormone)IBA 01/2022 - 02/2008
2	Adenosine-5'-(N-ethylcarboxamide) (NECA)IBA 01/2022 - 12/2016
2	LipidsIBA 01/2021 - 01/2016
2	NF-kappa B (NF-kB)IBA 01/2020 - 10/2002
2	Complement System Proteins (Complement)IBA 01/2020 - 02/2010
2	ProteomeIBA 01/2020 - 01/2011
2	Methionine (L-Methionine)FDA Link 01/2016 - 07/2002
2	Dosage Forms (Dosage Form)IBA 12/2015 - 12/2012
2	ProdrugsIBA 09/2015 - 07/2002
2	tanshinoneIBA 05/2012 - 01/2010
2	galbanic acidIBA 01/2012 - 03/2011
2	SynaptophysinIBA 09/2011 - 05/2009
2	Glucose (Dextrose)FDA LinkGeneric 06/2011 - 09/2009
2	Biological ProductsIBA 02/2011 - 09/2009
2	Transcription Factors (Transcription Factor)IBA 01/2010 - 10/2002
2	Conditioned Culture MediaIBA 01/2010 - 06/2007
2	Cyclin D1IBA 05/2009 - 03/2009
2	Caspase 9IBA 06/2007 - 07/2006
2	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2007 - 11/2005
2	hydrogen selenideIBA 11/2005 - 10/2002
2	Sodium SeleniteIBA 08/2005 - 10/2002
1	Histones (Histone)IBA 01/2020
1	Glutathione (Reduced Glutathione)IBA 01/2020
1	ChromatinIBA 01/2020
1	TransferasesIBA 01/2020
1	PeroxidasesIBA 01/2020
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2016
1	oncofetal antigensIBA 12/2015
1	Polysaccharides (Glycans)IBA 12/2012
1	SolventsIBA 10/2012
1	Chalcone (Benzalacetophenone)IBA 09/2012
1	bicalutamide (Casodex)FDA LinkGeneric 06/2012
1	ethyl acetateIBA 02/2012
1	Cadherins (E-Cadherin)IBA 09/2011
1	Tumor Viral Antigens (Large T Antigen)IBA 09/2011
1	GalactosidasesIBA 08/2011
1	PhytochemicalsIBA 01/2011
1	Angiogenesis InhibitorsIBA 01/2011
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2011

Therapy/Procedure

17	Chemoprevention 01/2020 - 10/2002
4	Therapeutics 01/2014 - 09/2008
3	Oral Administration 06/2012 - 08/2010
1	Euthanasia (Mercy Killing) 12/2015